Tag Archives: Ram Selvaraju

H.C. Wainwright Sticks to Their Buy Rating for Microbot Medical Inc (MBOT)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Microbot Medical Inc (MBOT – Research Report) today and set a price target of $10. The company’s shares closed last Monday at $5.42. Selvaraju observed: “Our price target is derived

Analysts Offer Insights on Healthcare Companies: Nucana Plc (NASDAQ: NCNA), Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) and Trillium Therapeutics (NASDAQ: TRIL)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nucana Plc (NCNA – Research Report), Entasis Therapeutics Holdings Inc (ETTX – Research Report) and Trillium Therapeutics (TRIL – Research Report). Nucana Plc (NCNA) H.C.

Urovant Sciences Ltd (UROV) Receives a Buy from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Urovant Sciences Ltd (UROV – Research Report), with a price target of $28. The company’s shares closed last Monday at $7.54. Selvaraju commented: “We have

H.C. Wainwright Reiterates Their Buy Rating on Equillium Inc (EQ)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Equillium Inc (EQ – Research Report) today and set a price target of $14. The company’s shares closed last Monday at $3.56, close to its 52-week low of $3.10. Selvaraju

Repligen Corp (RGEN) Gets a Buy Rating from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Repligen Corp (RGEN – Research Report), with a price target of $110. The company’s shares closed on Friday at $91.84, close to its 52-week high

H.C. Wainwright Thinks Synlogic Inc’s Stock is Going to Recover

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Synlogic Inc (SYBX – Research Report), with a price target of $22. The company’s shares closed on Friday at $5.46, close to its 52-week low